Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Immunol Res

Department of Microbiology, University of Pennsylvania School of Medicine, 323 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA, 19104-6076, USA.

Published: March 2009

Our laboratory is interested in how immunogenicity may be modulated in vivo in order to better design more effective immunotherapeutics against cancer. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic CTL epitopes. We have used this approach to target tumor antigens expressed on breast, melanoma and cervical cancer. We are also exploring the role of Listerial virulence factors in potentiating adaptive immune responses by activating innate immunity. Specifically, we are using these proteins as adjuvants for B cell lymphomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763613PMC
http://dx.doi.org/10.1007/s12026-008-8087-0DOI Listing

Publication Analysis

Top Keywords

listeria monocytogenes
8
listerial virulence
8
virulence factors
8
cancer immunotherapy
4
immunotherapy listeria
4
monocytogenes listerial
4
factors laboratory
4
laboratory interested
4
interested immunogenicity
4
immunogenicity modulated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!